Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.J. Whithey.
Virus varicela-zoster.
Principles and practice of infectious diseases, 5th ed, pp. 1931-1938
[2.]
S.R. Preblud, W.A. Orestein, K.J. Bart.
Varicella: clinical manifestations, epidemiology and health impact in children.
Pediatr Infect Dis J, 3 (1984), pp. 505-509
[3.]
A.H. Ross.
Modifications of chickenpox in family contacts by administration of gamma globulin.
N Engl J Med, 267 (1962), pp. 369-376
[4.]
J.D. Meyers.
Congenital varicella in term infants; risk reconsidered.
J Infect Dis, 129 (1974), pp. 215-217
[5.]
S.R. Preblud.
Age-specific risks of varicella complications.
Pediatrics, 68 (1981), pp. 14-17
[6.]
S.F. Feldman, W.T. Hughes, C.B. Daniel.
Varicella in children with cancer: seventy-seven cases.
Pediatrics, 56 (1975), pp. 388-397
[7.]
O.L. Laskin.
Acyclovir: pharmacology and clinical experience.
Arch Intern Med, 144 (1984), pp. 1241-1246
[8.]
A.M. Arvin.
Oral therapy with acyclovir in infants and children.
Pediatr Infect Dis J, 6 (1987), pp. 56-58
[9.]
S.M. Croze, C.A. Stoikides.
Oral acyclovir in immunocompetent patients with varicella.
Ann Pharmacother, 28 (1994), pp. 208-209
[11.]
K. Galil, C. Brown, F. Lin, J. Seward.
Hospitalizations for varicella in the United States, 1988 to 1999.
Pediatr Infect Dis J, 21 (2002), pp. 931-935
[12.]
Centers for Disease Control and Prevention. Infectious diseases information: varicella- zoster virus. CDC: National Center for Infectious Diseases, 2001. Disponible en: http://www.cdc.gov/ncidod/diseases/list_varaicl.htm
[13.]
D.A. Moore, R.S. Hopkins.
Assessment of a school exclusion policy during a chickenpox outbreak.
Am J Epidemiol, 133 (1991), pp. 1161-1167
[14.]
Canadian Pediatric Society(CPS).
School and daycare exclusion policies for chickenpox: a rational approach. Infectious Diseases Immunization Committee, Canadian Paediatric Society.
Pediatr Child Health, 4 (1999), pp. 287-288
[15.]
H.H. Balfour, J.M. Kelly, C.S. Suarez, R.C. Heussner, J.A. Englun, D.D. Crane, et al.
Acyclovir treatment of varicella in otherwise healthly children.
J Pediatr, 116 (1990), pp. 633-639
[16.]
L.M. Dunkle, A.M. Arvin, R.J. Whitley, H.A. Rotbart, H.M. Feder, S. Feldman, et al.
A controlled trial of acyclovir for chickenpox in normal children.
N Engl J Med, 325 (1991), pp. 1539-1544
[17.]
H.H. Balfour, H.A. Rotbart, S. Feldman, L.M. Dunkle, H.M. Feder, C.G. Prober, et al.
Acyclovir treatment of varicella in otherwise healthy adolescents.
J Pediatr, 120 (1992), pp. 627-633
[18.]
A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J.M. Reynolds, D.J. Gavaghan, et al.
Assessing the quality of reports of randomised clinical trials: is blinding necessary.
Control Clin Trials, 17 (1996), pp. 1-12
[19.]
D.E. Barnes, L.A. Vero.
Why review articles on the health effects of passive smoking reach different conclusions.
Jama, 279 (1998), pp. 1566-1570
[20.]
M.K. Cho, L.A. Vero.
The quality of drug studies published in symposium proceedings.
Ann Intern Med, 124 (1986), pp. 485-489
[21.]
H.H. Balfour, C.K. Edelman, R.S. Anderson, N.V. Reed, R.M. Slivken, L.H. Marmor, et al.
Controlled trial of acyclovir for chickenpox evaluating time of initiation and duration of therapy and viral resistance.
Pediatr Infect Dis J, 20 (2001), pp. 919-926
[22.]
A. Mouzard.
Traitment par antiviral de la varicelle du Nourrisson et de l'enfant: les arguments contre.
Med Mal Infect, 28 (1998), pp. 832-836
[23.]
M.W. McKendrick.
Acyclovir for childhood. Cost is unjustified.
Bmj, 310 (1995), pp. 108-109
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados